What Hope Biosciences does

Hope Biosciences is a private biopharmaceutical company founded in 2016 and headquartered in Sugar Land, Texas, that develops and commercializes mesenchymal stem cell (MSC) therapeutics built on a proprietary HB-101 culture media and patented cell expansion process. The company's core technology isolates MSCs from adult adipose tissue or newborn placental tissue and expands them into Master Cell Banks capable of generating more than 1,000 therapeutic doses per client with a five-day fresh-cell viability window. Hope operates three distinct revenue lines: subscription-based private stem cell banking services for adults and newborns, contract manufacturing of HB-adMSCs for FDA-authorized clinical trials conducted through academic partners, and consumer products including the Wondercell skincare serum and Wonderstem conditioned media sold via its e-commerce store.

The company has accumulated approximately 50 FDA-authorized clinical protocols spanning indications such as multiple sclerosis, Parkinson's, Alzheimer's, traumatic brain injury, ALS, rheumatoid arthritis, Crohn's disease, multiple system atrophy, and acute kidney injury, and secured FDA Regenerative Medicine Advanced Therapy (RMAT) designation for relapsing-remitting MS. A $4.9 million Department of Defense CDMRP grant funds a Phase II TBI trial at UTHealth Houston, and a new frozen allogeneic HB-adMSC product was launched in February 2026 for acute kidney injury across a multicenter trial network. An affiliated nonprofit, Hope Biosciences Research Foundation, operates as an in-house clinical trial site. The company is founder-led by CEO Donna Chang, operates with 11-50 employees, and serves customers across approximately five countries including the United States and the Philippines.

Name

Hope Biosciences

Legal name

Hope Biosciences, LLC

Website

https://hope.bio

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Hope Biosciences is a private Sugar Land, Texas biopharmaceutical company that uses proprietary HB-101 culture media to bank and expand mesenchymal stem cells for adults and newborns, supply HB-adMSC therapeutics to FDA-authorized clinical trials, and sell consumer skincare products.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

• Stem cell banking
• Mesenchymal stem cells
• Cellular therapeutics
• Regenerative medicine
• Biopharmaceutical research

Headquarters

HQ city

Sugar Land

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Stem Cell Banking Services: Private stem cell banking services for adults and newborns, providing Master Cell Banks that can generate over 1,000 therapeutic doses for lifetime use. Revenue generated through banking service fees.
2. Skincare Products: Sale of Wondercell Gel skincare serum and Wonderstem conditioned media for cosmetic and research applications. Products sold through company e-commerce platform.
3. Clinical Research Services: Manufacturing and supplying cellular therapeutics for FDA-authorized clinical trials in partnership with academic institutions and research organizations.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

Hope Biosciences is a biopharmaceutical company that isolates, cultures, and banks mesenchymal stem cells (MSCs) from adult adipose tissue and newborn placental tissue using its proprietary HB-101 culture media. It produces clinical-grade Master Cell Banks capable of generating over 1,000 fresh therapeutic doses per client for lifetime use, supplies HB-adMSCs to FDA-authorized clinical trials, and sells derivative consumer and research products (Wondercell Gel, Wonderstem conditioned media).

Product overview

Hope Biosciences is a biopharmaceutical company offering a portfolio of stem cell-based products and services centered on its proprietary mesenchymal stem cell (MSC) culture and banking technology. The core offering is clinical-grade private stem cell banking (for both adults and newborns), which creates Master Cell Banks capable of generating over 1,000 fresh therapeutic doses per client. Hope Biosciences also manufactures HB-adMSCs (adipose-derived mesenchymal stem cells) using patented cell culture media (HB-101) for use in FDA-authorized clinical trials. Consumer-facing products include Wondercell® Gel skincare serum (launched 2022), containing Wonderstem® conditioned media — a stem cell-derived bioactive growth factor ingredient. The company additionally sells Wonderstem® Conditioned Media as a raw material for research and cosmetic development. The company is expanding into frozen MSC therapeutics with its first frozen product for acute conditions such as Acute Kidney Injury.

Differentiator

Problem solved

Functional benefit

Brands

• Wondercell: Skincare serum product derived from stem cell technology, containing Wonderstem protein-rich byproduct for skin rejuvenation
• Wonderstem
• Stem Cell Revolution (SCR)
• Hopeful News Network (HNN)

Products and services

• Adult Stem Cell Banking Autologous stem cell banking that extracts mesenchymal stem cells from adult adipose (fat) tissue, expands them via Hope Biosciences' proprietary HB-101 culture media, and stores them as a Master Cell Bank capable of generating fresh therapeutic doses on demand for the client's future treatments.
• Newborn Stem Cell Banking Stem cell banking service that extracts pure mesenchymal stem cells from the amniotic membrane of the placenta at birth, creating a Master Cell Bank from which over 1,000 therapeutic doses can be generated over a lifetime.
• HB-adMSC Therapeutic (Mesenchymal Stem Cell Therapeutics) Proprietary adipose-derived mesenchymal stem cells (HB-adMSCs) manufactured using patented cell culture technology, supplied to academic and clinical research organizations for use in FDA-authorized clinical trials spanning neurodegenerative, autoimmune, traumatic injury, and inflammatory indications.
• Frozen HB-adMSC Therapeutic A frozen allogeneic adipose-derived mesenchymal stem cell product developed for acute emergency settings such as Acute Kidney Injury (AKI), representing Hope Biosciences' first frozen stem cell product.
• Wondercell Gel A shelf-stable multi-use skincare serum containing Wonderstem, a protein-rich stem cell-derived byproduct (bioactive growth factors) that promotes collagen production, hyaluronic acid synthesis, skin elasticity, and wound healing when applied topically to face and body.
• Wonderstem Conditioned Media Conditioned media harvested from Hope Biosciences' proprietary MSC culture process, containing human growth factors and proteins (Procollagen, EGF, VEGF, FGF, HGF, KGF, IGF-I, TGF-b, SDF-1a, Fibronectin); sold ready-to-use and in bulk for drug development, IV and topical research, and cosmetic formulation.

Quantifiable outcome

• Over 1,000 therapeutic doses generated per Master Cell Bank
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core, supporting and minor.

• University of Alabama at BirminghamcoreStrategic or Co-development Partner · 3 February 2026Clinical trial site for multicenter Phase 1/2a acute kidney injury trial (NCT06654193). One of three sites recruiting trauma and burn patients across southwestern United States.
• University of California at San FranciscocoreStrategic or Co-development Partner · 3 February 2026Clinical trial site for multicenter Phase 1/2a acute kidney injury trial (NCT06654193). Site expected to begin recruitment soon.
• Wake Forest Institute for Regenerative MedicinesupportingStrategic or Co-development Partner · 3 February 2026Supporting agency for acute kidney injury trial, contributing expertise in regenerative medicine research.
• UTHealth HoustoncoreStrategic or Co-development Partner · 1 June 2023Multi-year collaboration for traumatic brain injury clinical trials. UTHealth Houston serves as lead research institution with Dr. Charles S. Cox Jr. as principal investigator. Collaboration includes Phase I/IIa trial (NCT04063215) and DoD-funded Phase II trial (NCT05951777) with 51 participants across Houston and San Antonio sites. Also partnered for Alzheimer's disease Phase Ib/IIa trial.
• Hope Biosciences Research Foundation (HBRF)coreStrategic or Co-development PartnerNon-profit 501(c)(3) organization headquartered in Sugar Land, Texas serving as clinical trial site for MSA, Crohn's disease, MS and other conditions. Founded in 2020, works primarily with chronic conditions.
• UTHealthcoreStrategic or Co-development PartnerUniversity of Texas Health Science Center at Houston; logo displayed on company website indicating research partnership.
• University of HoustonminorStrategic or Co-development PartnerAcademic partnership for research collaboration and student engagement.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Celltex Therapeutics: Houston-based autologous adult stem cell banking and therapy company using adipose-derived MSCs. Direct competitor to Hope Biosciences' adult banking business and a fellow Texas-based MSC clinical player.
• Mesoblast: Commercial-stage MSC therapy company developing remestemcel-L and other allogeneic MSC products. Closest publicly-traded pure-play MSC therapeutic comparable, validating the regulatory pathway Hope Biosciences is pursuing.
• BrainStorm Cell Therapeutics: Developer of NurOwn, an autologous MSC-based therapy for ALS and MS. Direct therapeutic peer overlapping Hope Bio's neurological indications (ALS, MS) and using MSC platform technology.
• Pluristem Therapeutics: Placental-derived MSC therapy developer with allogeneic platform for inflammatory and ischemic conditions. Comparable in cell source, allogeneic approach, and therapeutic focus on acute and chronic inflammatory diseases.
• ViaCord: PerkinElmer-owned cord blood and tissue banking service for newborns. Directly comparable consumer-facing newborn stem cell banking model, though focused on hematopoietic rather than mesenchymal cells.
• Cord Blood Registry (CBR): Largest U.S. newborn stem cell bank, acquired by CooperCompanies. Direct competitor in the D2C newborn banking segment, with overlap in marketing channels and target customer (expectant parents).

Emerging players

• Celularity Inc. Cellular therapeutics company with MSC and placenta-derived cell programs. Comparable in cell source strategy and clinical development across multiple indications, with broader pipeline including NK cells.
• Americord Registry: D2C cord blood, cord tissue, and exosome banking company. Comparable in D2C stem cell banking go-to-market, though operating at smaller scale than Hope Bio's clinical-grade positioning.

Broad incumbents

• Lonza Cell & Gene Technologies: Global cell therapy CDMO offering MSC manufacturing services. Comparable on the cGMP manufacturing capability Hope Bio operates internally, and a potential strategic partner or competitor for contract MSC production.

Regional players

• StemCyte: U.S. and Asia-based cord blood bank with therapeutic applications. Comparable as a privately-held stem cell banking peer with both consumer and clinical trial supply operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/hopebiosciences
• YouTubeyoutube.com/channel/UCfQeFTtclHeGT6Nz3cl2rDQ/videos?view_as=subscriber
• Facebookfacebook.com/hopebiosciences
• LinkedInlinkedin.com/company/19003862
• Instagraminstagram.com/hope.bio
• Pinterestpinterest.com/hopebio

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hope Biosciences